US equities |
AAPL $349.51 ▲+5.31% NVDA $200.13 ▼-3.17% MU $795.23 ▼-7.00% MSFT $555.80 ▲+6.68% AMD $488.78 ▲+1.01% AMZN $266.03 ▲+6.12% META $630.00 ▲+1.44% TSLA $385.19 ▼-3.34%
FinancialContent

Crescita Therapeutics Inc (OP:CRRTF)

0.5587 UNCHANGED
Last Price Updated: 3:37 PM EDT, May 27, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Crescita Therapeutics Inc

News headline image
Crescita Reports Second Quarter 2025 Results
From Crescita Therapeutics Inc.
Via Business Wire
News headline image
Crescita Therapeutics Announces the Results of its Annual General and Special Meeting of Shareholders
From Crescita Therapeutics Inc.
Via Business Wire
News headline image
Crescita Therapeutics Announces Mutual Termination of Licensing Agreement with Croma Pharma GmbH for Pliaglis®
From Crescita Therapeutics
Via Business Wire
News headline image
Crescita Reports First Quarter 2025 Results
From Crescita Therapeutics Inc.
Via Business Wire
News headline image
Crescita Reports Q4 and Fiscal 2024 Results
From Crescita Therapeutics
Via Business Wire
News headline image
Crescita Reports Third Quarter 2024 Results
From Crescita Therapeutics
Via Business Wire
News headline image
Crescita Therapeutics Announces Approval of Normal Course Issuer Bid
From Crescita Therapeutics
Via Business Wire
News headline image
Crescita to Present & Participate in 1x1 Meetings at the Planet MicroCap Showcase: VANCOUVER 2024 in Association with Small Cap Discoveries on Thursday, September 26, 2024
From Crescita Therapeutics
Via Business Wire
News headline image
Crescita Reports Second Quarter 2024 Results
From Crescita Therapeutics
Via Business Wire
News headline image
Crescita Secures Contract Manufacturing Revenue of $US10 Million Over 4 Years
From Crescita Therapeutics
Via Business Wire
News headline image
Leading Canadian Healthcare Services Provider Selects Crescita as Exclusive Manufacturing Partner under 5-Year Agreement
From Crescita Therapeutics
Via Business Wire
News headline image
Crescita Expands Medical Aesthetic Portfolio with MicronJetTM600 The World’s Smallest Intradermal Delivery Device
From Crescita Therapeutics
Via Business Wire
News headline image
Crescita Completes Acquisition of Strategic Assets of Occy Laboratory
From Crescita Therapeutics
Via Business Wire
News headline image
Crescita to Acquire Strategic Assets of Occy Laboratory
From Crescita Therapeutics
Via Business Wire
News headline image
Crescita Reports First Quarter 2024 Results
From Crescita Therapeutics
Via Business Wire
News headline image
Crescita Reports Q4 and Fiscal 2023 Results
From Crescita Therapeutics
Via Business Wire
News headline image
Crescita Reports Third Quarter 2023 Results
From Crescita Therapeutics Inc.
Via Business Wire
News headline image
Crescita Therapeutics Announces Approval of Normal Course Issuer Bid
From Crescita Therapeutics
Via Business Wire
News headline image
Crescita Reports Second Quarter 2023 Results
From Crescita Therapeutics
Via Business Wire
News headline image
Crescita Therapeutics Announces the Results of its Annual General and Special Meeting of Shareholders
From Crescita Therapeutics
Via Business Wire
News headline image
Crescita Reports First Quarter 2023 Results
From Crescita Therapeutics Inc.
Via Business Wire
News headline image
Crescita Reports Q4 and Fiscal 2022 Results
From Crescita Therapeutics Inc.
Via Business Wire
News headline image
Crescita Reports Third Quarter 2022 Results
From Crescita Therapeutics Inc.
Via Business Wire
News headline image
Crescita Reports Second Quarter 2022 Results
From Crescita Therapeutics Inc.
Via Business Wire
News headline image
Crescita Therapeutics Announces the Results of its Annual General and Special Meeting of Shareholders
From Crescita Therapeutics
Via Business Wire
News headline image
Crescita Reports First Quarter 2022 Results
From Crescita Therapeutics
Via Business Wire
News headline image
Crescita to Present at Bloom Burton & Co. Healthcare Investor Conference
From Crescita Therapeutics
Via Business Wire